486 related articles for article (PubMed ID: 28247187)
1. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry Prediction for Clinical Translation of
Natarajan A; Patel CB; Habte F; Gambhir SS
Sci Rep; 2018 Jan; 8(1):633. PubMed ID: 29330552
[TBL] [Abstract][Full Text] [Related]
3. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes.
Natarajan A; Mayer AT; Xu L; Reeves RE; Gano J; Gambhir SS
Bioconjug Chem; 2015 Oct; 26(10):2062-9. PubMed ID: 26307602
[TBL] [Abstract][Full Text] [Related]
4. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
[TBL] [Abstract][Full Text] [Related]
5. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
6. A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues.
Natarajan A; Patel CB; Ramakrishnan S; Panesar PS; Long SR; Gambhir SS
Clin Cancer Res; 2019 Mar; 25(6):1774-1785. PubMed ID: 30373750
[TBL] [Abstract][Full Text] [Related]
7. Immuno-PET Imaging of
Li D; Cheng S; Zou S; Zhu D; Zhu T; Wang P; Zhu X
Mol Pharm; 2018 Apr; 15(4):1674-1681. PubMed ID: 29502426
[TBL] [Abstract][Full Text] [Related]
8.
Bridgwater C; Geller A; Hu X; Burlison JA; Zhang HG; Yan J; Guo H
Cancer Biother Radiopharm; 2020 Oct; 35(8):549-557. PubMed ID: 32315549
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
[TBL] [Abstract][Full Text] [Related]
11. Probody Therapeutic Design of
Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
[TBL] [Abstract][Full Text] [Related]
12. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
[TBL] [Abstract][Full Text] [Related]
13. PET/CT Imaging of
Li W; Wang Y; Rubins D; Bennacef I; Holahan M; Haley H; Purcell M; Gantert L; Hseih S; Judo M; Seghezzi W; Zhang S; van der Veen EL; Lub-de Hooge MN; de Vries EGE; Evelhoch JL; Klimas M; Hostetler ED
Mol Imaging Biol; 2021 Apr; 23(2):250-259. PubMed ID: 33104972
[TBL] [Abstract][Full Text] [Related]
14. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
15. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
[TBL] [Abstract][Full Text] [Related]
16. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
[TBL] [Abstract][Full Text] [Related]
17. Imaging diagnosis and efficacy monitoring by [
He H; Qi X; Fu H; Xu J; Zheng Q; Chen L; Zhang Y; Hua H; Xu W; Xu Z; Chen X; You Q; Lin J; Huang G; Mao Y; Yu C
Theranostics; 2024; 14(1):392-405. PubMed ID: 38164149
[No Abstract] [Full Text] [Related]
18. Synthesis and Biologic Evaluation of a Novel
Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of
Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C
J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891
[TBL] [Abstract][Full Text] [Related]
20.
van der Veen EL; Giesen D; Pot-de Jong L; Jorritsma-Smit A; De Vries EGE; Lub-de Hooge MN
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
